Last reviewed · How we verify
Entecavir prophylaxis
At a glance
| Generic name | Entecavir prophylaxis |
|---|---|
| Also known as | Baraclude |
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP (PHASE3)
- Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors (PHASE4)
- Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation (NA)
- Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) (PHASE2)
- Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc) (NA)
- Extension Study of Carvedilol RCT Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Entecavir prophylaxis CI brief — competitive landscape report
- Entecavir prophylaxis updates RSS · CI watch RSS
- Taipei Veterans General Hospital, Taiwan portfolio CI